the development of toxicity should be monitored on a regular basis by specifically asking the patient whether there has been any subjective hearing loss , ear fullness , tinnitus , or vertigo supplemented by pretreatment and follow-up audiogram and electronystagmogram ( eng ) .
C0011053
hearing loss
C0013443
ear